NCT00962585 - Efficacy and Safety of S-equol on Vasomotor Symptoms in Menopausal Patients | Biotech Hunter

Enrollment

169

Participants

Timeline

Start Date

June 30, 2010

Primary Completion Date

November 30, 2011

Study Completion Date

November 30, 2011

Conditions

Menopause

Interventions

DRUG

Placebo

DRUG

S-equol

"Eligible patients meeting all study entry criteria were randomly assigned to receive one of the following active treatments for 4 weeks:~* S-equol 10 mg BID (20 mg total daily dose)~* S-equol 50 mg BID (100 mg total daily dose)~* S-equol 150 mg BID (300 mg total daily dose)"

Trial Locations (9)

2031

Royal Hospital for Women, Randwick

2131

Sydney Centre for Reproductive Health Research, Ashfield

3144

Emeritus Research, Malvern East

5000

Women's Health Center, Royal Adelaide Hospital, Adelaide

29621

Radiant Research, Inc, Greenville

40291

Bluegrass Clinical Research, Louisville

44122

Rapid Medical Research, Cleveland

84088

Advanced Clinical Research, West Jordon

45267-0457

Greater Cincinnati OB/GYN, Inc., Cincinnati